These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 18752077)

  • 21. [Pharmacoeconomical analysis of antibiotic use at the Clinic For Infectious Diseases of the Clinical Center of Vojvodina].
    Stefan-Mikić S; Jovanović J; Jovanović N; Sević S; Vukadinov J; Miucin-Vukadinović I
    Med Pregl; 2008; 61 Suppl 1():40-9. PubMed ID: 19248639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New antimicrobial agents for use in the intensive care unit.
    Ritchie DJ; Alexander BT; Finnegan PM
    Infect Dis Clin North Am; 2009 Sep; 23(3):665-81. PubMed ID: 19665089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens.
    Fraimow HS; Tsigrelis C
    Crit Care Clin; 2011 Jan; 27(1):163-205. PubMed ID: 21144992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial therapy and aerobic bacteriologic culture patterns in canine intensive care unit patients: 74 dogs (January-June 2006).
    Black DM; Rankin SC; King LG
    J Vet Emerg Crit Care (San Antonio); 2009 Oct; 19(5):489-95. PubMed ID: 19821892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methods of documenting cost savings associated with an antibiotic management program.
    Lacy MK; Eidem LA; Bond JA; Swartz MA
    Pharm Pract Manag Q; 1996 Jul; 16(2):66-70. PubMed ID: 10161615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of limiting antimicrobial therapy duration on antimicrobial resistance in the critical care setting.
    Marra AR; de Almeida SM; Correa L; Silva M; Martino MD; Silva CV; Cal RG; Edmond MB; dos Santos OF
    Am J Infect Control; 2009 Apr; 37(3):204-9. PubMed ID: 18986735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing antibacterial pharmacoeconomics in the intensive care unit.
    Birmingham MC; Hassett JM; Schentag JJ; Paladino JA
    Pharmacoeconomics; 1997 Dec; 12(6):637-47. PubMed ID: 10175976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Navigating the Web in search of resources on antimicrobial stewardship in health care institutions.
    Pagani L; Gyssens IC; Huttner B; Nathwani D; Harbarth S
    Clin Infect Dis; 2009 Mar; 48(5):626-32. PubMed ID: 19191651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Essential characteristics of antibiotics for the treatment of seriously ill patients.
    Moellering RC
    Clin Ther; 1981; 4 Suppl A():1-7. PubMed ID: 7326692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Microbial spectrum in surgical infections based on a microbiological routine monitoring over the 10-year period from 1995 to 2004].
    Mroczkowski P; Lauf H; Lippert H; König W; Meyer F
    Zentralbl Chir; 2009 Jun; 134(3):226-30. PubMed ID: 19536716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Economic aspects of intensive care medicine--cost and reimbursement according to diagnosis related grouping].
    Billing A; Thalhammer M; Eissner HJ; Jauch KW; Inthorn D
    Zentralbl Chir; 2004 Dec; 129(6):440-6. PubMed ID: 15616906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategic alliance between the infectious diseases specialist and intensive care unit physician for change in antibiotic use.
    Curcio D; Belloni R
    J Chemother; 2005 Feb; 17(1):74-6. PubMed ID: 15828447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with thromboembolic or infarction-related events.
    MacLaren R; Bond CA
    Pharmacotherapy; 2009 Jul; 29(7):761-8. PubMed ID: 19558249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic burden of antibiotic treatment of healthcare-associated infections at a tertiary care hospital ICU in Goa, India.
    Misal DD; Maulingkar SV; Bhonsle S
    Trop Doct; 2017 Jul; 47(3):197-201. PubMed ID: 27307475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economics and outcome in the intensive care unit.
    Pittoni GM; Scatto A
    Curr Opin Anaesthesiol; 2009 Apr; 22(2):232-6. PubMed ID: 19390250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antibiotics and health care economics].
    Modai J; Droulers AM
    Soins; 1981 Mar; 26(6):38-9. PubMed ID: 6910261
    [No Abstract]   [Full Text] [Related]  

  • 38. Economics of antibiotic use policies.
    Paladino JA
    Pharmacotherapy; 2004 Dec; 24(12 Pt 2):232S-8S. PubMed ID: 15585453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens.
    Scaglione F; Paraboni L
    Int J Antimicrob Agents; 2008 Oct; 32(4):294-301. PubMed ID: 18621508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Main variables in the economic cost of treating an infection].
    Grau S
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():41-45. PubMed ID: 28129821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.